Diadem Appoints Michael Rasche as Chief Executive Officer
2024年7月10日 - 8:00PM
Diadem SpA, (Diadem), a company developing one of the first
blood-based tests for the early and accurate prediction of clinical
progression to Alzheimer’s disease (AD), today announced that
Michael Rasche has been named Chief Executive Officer (CEO) and a
member of the Board of Directors. Mr. Rasche brings Diadem more
than three decades of experience in driving life sciences
innovations to commercial success across Europe and the Americas.
The company also announced that former CEO Paul Kinnon
will continue to serve on the Diadem SpA board and has been named
Chairman of Diadem US, Inc.
Dr. Gerald Möller, Chair of Diadem’s Board of Directors,
commented, “I am delighted that Michael will be leading Diadem at
this exciting time for the company. Michael’s broad experience
spans leadership roles in market development, sales and general
management in our industry. His drive, skills and commitment have
enabled him to successfully commercialize multiple innovative
products. The growing number of therapeutic options for AD
highlight the importance of identifying and monitoring Alzheimer’s
patients early, with growing evidence that early interventions can
slow disease progression. Our AlzoSure® prognostic
test can accurately identify individuals who will progress to AD
years before the disease manifests. With Michael on board and
Paul´s continued activities we will be optimally positioned for the
upcoming growth phase of Diadem.
Mr. Rasche noted, “I am thrilled at the opportunity to lead
Diadem as we move to rapidly commercialize the
AlzoSure® products—a truly innovative approach to
improving the management of Alzheimer’s disease. Diadem has already
amassed an impressive amount of clinical data demonstrating the
accuracy and utility of AlzoSure® as a prognostic
test for AD, and our research suggests additional applications as
well. I look forward to working with our team and our partners to
advance our business and ensure that the benefits of
AlzoSure® are widely available to relevant
stakeholders around the globe.”
Michael Rasche has more than 30 years of leadership experience
in high growth international healthcare and life sciences firms
across Europe and the Americas. Most recently, he was Chief
Commercial Officer at transformational diagnostics firm
miDiagnostics. Previously Rasche was President and General Manager
of International Business at Metabolon, where he oversaw operations
and commercial activities during a period of very rapid growth. At
Definiens, an AstraZeneca company, Rasche helped expand the
business as Chief Commercial Officer, achieving 50% growth and
setting the stage for major partnering agreements. He has also held
leadership positions with Ayoxxa, Dako (now part of Agilent), Roche
and Bayer Diagnostics.
Diadem’s AlzoSure® Predict is a non-invasive
biomarker blood test that can identify with high accuracy whether
individuals over the age of 50 will experience significant
cognitive decline due to Alzheimer’s disease up to six years before
the onset of symptoms. Its utility is supported by clinical data
from a large longitudinal study that was the basis for
AlzoSure® Predict’s CE-IVD marking clearance and a
Breakthrough Device designation from the U.S. Food & Drug
Administration. Diadem has formed a strategic collaboration
granting Quest Diagnostics exclusive U.S. rights to the
intellectual property of the AlzoSure® Predict mass spectrometry
assay for the purpose of developing, validating and marketing a
laboratory-developed test service for U.S. providers and
patients.
About AlzoSure®
TechnologyAlzoSure® Predict uses a proprietary
antibody (U-p53AZ) to measure blood levels of a conformational
variant of the p53 protein that has been implicated in the
pathogenesis of AD. The utility of AlzoSure®
Predict is supported by a large body of clinical data, including
data from a longitudinal study that was the basis for
AlzoSure® Predict’s Breakthrough Device
designation from the U.S. FDA and its CE-IVD marking in the E.U.
AlzoSure® Predict requires only 1mL of blood to
detect the risk of Alzheimer’s disease at the asymptomatic and
early symptomatic stage. In addition, the
AlzoSure® Predict products can identify “rapid
progressors” at high risk of progressing to Alzheimer’s disease
within two years. Diadem is also developing AlzoSure® Confirm for
the differential diagnosis of Alzheimer’s disease and other
dementias. AlzoSure® Confirm is a blood-based assay that uses a
different set of protein fingerprints to measure levels of the
unfolded p53 protein in order to distinguish between and predict
whether or not individuals will decline to AD, frontotemporal
dementia, Lewy body dementia or Parkinson’s disease-associated
dementia. Clinical validation studies are underway.
About Diadem Diadem was founded as a spin-out
of the University of Brescia (Italy). The company is developing the
first blood-based prognostic test for the early detection of
dementia, with a focus on Alzheimer’s disease. The lack of
accurate, accessible and affordable diagnostic tools has
contributed to the lack of effective treatments for this
devastating condition. As a result, patients have not been
diagnosed until late in the illness, when effective treatment is
less feasible. Diadem’s rapid, accurate and cost-effective
AlzoSure® Predict blood-based prognostic test
makes it possible to identify patients early in the disease
process, when effective interventions and better outcomes are
potentially achievable. The utility of the approach has been
demonstrated in longitudinal clinical studies that were the basis
for awarding CE-IVD marking in the E.U. and a Breakthrough Device
designation in the U.S. Additional retrospective and prospective
clinical trials are ongoing to further validate clinical claims and
support adoption and use. The company is also developing AlzoSure®
Confirm, a blood-based diagnostic test for AD that has shown
promising results in early studies. For more information, visit
diademdx.com.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/8e5a1c58-4816-4ab5-a4d5-f5a48efcea04
Contacts:
Corporate:
Diadem
Michael Rasche
CEO
ExecAdmin@Diademdx.com |
Media:Barbara Lindheim
BLL
Partners for Diadem
blindheim@bllbiopartners.com+1 (917) 355-9234
|